11.7.00: European Pharmaceuticals & Biotechnology Issue
Two leading analysts and top management from sixteen sector firms examine the outlook for European Pharmaceuticals & Biotechnology companies in the latest issue of The Wall Street Transcript.
  1. European Pharmaceuticals Stocks - In an in-depth (2,900) Analyst Interview, Stewart Adkins, Pharmaceutical Analyst at Lehman Brothers, examines the outlook for the sector, including genomics, management issues, and shares specific stock recommendations.
  2. European Pharmaceuticals Stocks - In an in-depth (2,900) Analyst Interview, Andrew Pendrill, Director of ABN AMRO Equities (UK) Limited, examines the outlook for the sector, including expiration point, biotechnology sub-segments, and shares specific stock recommendations.
  3. CEO/Company interviews (average 2,000 words). Top management of sixteen sector firms examine the outlook for their firm and the sector. Firms include:
    MediGene, GPC Biotech, app Implantate, CeNeS Pharmaceuticals, GrandVision Group, MorphoSys, OXiGENE, Peptide Therapeutics Group, Pharmagene, PPL Therapeutics, Ransom (William) & Son, ReGen Therapeutics, Virbac Laboratories, Protherics, Radstone Technology, Bioglan Pharma
  4. Additional CEO/Company interviews (average 2,000 words). Top management of two sector firms examine the outlook for their firm and the sector. Firms include:
    Johnston Press, South African Breweries
    5. ORDER THIS REPORT NOW! ONLY $175
    The report will be mailed first class. For fedex delivery, specify in the report details section and either include your fedex number or we will add $15 delivery charge. All sales are final.  Questions, call (212) 952-7433, or email us
    For immediate access online - click here to gain a password.
     
    Report details:  
    Your Name:  
    		 Company: 
    Address: 
    		 City: 
    State/Province:
    		 ZIP/Postal Code:
          		 Country:
    Phone:
    		 E-Mail:

    BILLING INFORMATION
    Credit Card
    		 Expiration Month/Year:
    Credit Card Number: 
     

     This Issue costs $175 - and is non-returnable.   

    The Wall Street Transcript does not endorse the views of any interviewee nor does it make stock recommendations.

     

Investors and Industry Execs.

The Wall Street Transcript has been used by investors and industry executives for 40 years as a unique tool for company and industry research.

TWST's roundtable panels and analyst interviews provide a sector perspective from Wall Street's best. 

Money manager interviews provide the view from the buy-side.

CEO interviews with hundreds of companies from the major sectors gives the company perspective right from the top.

Subscribe to a unique research tool for investors and industry executives. Call (212) 952 7433 or click here.

Sincerely,

Andrew Pickup
Publisher
HOME PRODUCTS SUBSCRIBE ABOUT ARCHIVE HOTLINE CONTACT EUROPE